Furthermore, when reovirus is combined with cetuximab, an anti-EGFR monoclonal antibody, it significantly enhances antibody-dependent cell-mediated cytotoxicity (ADCC) against CRC cells, regardless of the KRAS mutation status. The gene discussed is KRAS; the disease is colorectal carcinoma.